<DOC>
	<DOCNO>NCT00727181</DOCNO>
	<brief_summary>This trial design confirm clinical safety effectiveness Trifecta valve establish associated adverse event rate , clinical status indicate New York Heart Association ( NYHA ) functional classification , hemodynamic performance , hematology analysis .</brief_summary>
	<brief_title>An Observational , Prospective Evaluation Trifectaâ„¢ Valve</brief_title>
	<detailed_description>The clinical investigation multi-center , multi-country , prospective , non-randomized , observational study without concurrent match control , design evaluate safety effectiveness Trifecta valve . A maximum 120 subject require aortic valve replacement implant maximum 6 investigational site Europe . The sample size base late patient-years follow-up minimum 400 late patient-years experience require .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Aortic Valve Insufficiency</mesh_term>
	<criteria>1 . Patient require aortic valve replacement . ( Note : patient undergo concomitant procedure , e.g . coronary artery bypass grafting , valve repair , eligible study ) . 2 . Patient legal age host country . 3 . Patient ( legal guardian ) give write informed consent participation prior surgery . 4 . Patient willing undergo study procedure adhere data collection followup requirement . 1 . Patient pregnant nursing ( woman child bear potential must document negative pregnancy test within one week prior surgery ) . 2 . Patient already prosthetic valve ( ) site aortic valve . 3 . Patient require concomitant replacement tricuspid , pulmonary , mitral valve . 4 . Patient inability unwilling return require followup visit . 5 . Patient active endocarditis ( patient previous endocarditis must two document negative blood culture result prior enrollment ) . 6 . Patient acute preoperative neurological event define patient return baseline stabilize 30 day prior plan valve implantation surgery . 7 . Patient undergoing renal dialysis . 8 . Patient document history substance abuse within one year enrollment currently prison inmate . 9 . Patient currently participate study investigational drug device , patient previously participate investigational drug study complete 30day wash period . 10 . Patient Trifecta valve implant part study , device explanted . 11 . Preoperative evaluation indicate significant cardiovascular abnormality aortic dissection ventricular aneurysm . 12 . Patient life expectancy less two year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>aortic valve</keyword>
	<keyword>heart valve</keyword>
	<keyword>tissue valve</keyword>
	<keyword>bioprosthesis</keyword>
	<keyword>valve disorder</keyword>
	<keyword>valve disease</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>aortic valve stenosis</keyword>
	<keyword>aortic valve regurgitation</keyword>
</DOC>